vk2809
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2016 (NCT02927184)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Thyroid hormone receptor beta-1ACTIVATOR
THRB activator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- vk2809
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04173065 | Phase 2 | Nov 15, 2019 | Viking Therapeutics, Inc. |
| NCT02927184 | Phase 2 | Aug 1, 2016 | Viking Therapeutics, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Viking Therapeutics, Inc. | For profit | 2 | 2 | 1 | 2016 |
1 organizations
Page 1 / 1